Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.32 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23348229 | 0.93 | KCNJ5 (0.30) | KDM4EKCNJ5KCNJ3KCNQ1CACNA1C | |
| SCHEMBL23348227 | 0.92 | KCNJ5 (0.32) | KDM4EKCNJ5KCNJ3KCNQ1CACNA1C | |
| SCHEMBL23348407 | 0.90 | PDE1C (0.35) | KDM4EALDH1A1GRIA2GRIA4 | |
| SCHEMBL22156478 | 0.90 | KCNJ5 (0.32) | KDM4EKCNJ5KCNJ3KCNQ1CACNA1C | |
| SCHEMBL22156480 | 0.89 | KDM4E (0.32) | KDM4EPIK3CD | |
| SCHEMBL22155910 | 0.87 | PDE9A (0.35) | KDM4EKCNJ5KCNJ3KCNQ1CACNA1C | |
| SCHEMBL23348514 | 0.87 | KCNJ5 (0.31) | KCNJ5KCNJ3KCNQ1CACNA1C | |
| SCHEMBL22155911 | 0.86 | PDE9A (0.36) | KDM4EPGRALDH1A1HSD17B10 | |
| SCHEMBL22156494 | 0.85 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL23348226 | 0.85 | SMN1; SMN2 (0.36) | KDM4EKCNJ5KCNJ3KCNQ1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139425-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-05-13 | — | — | US | disclosed |
| US-9527885-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139425-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CCND2, CCND1, CRY1 | KDM4E 3983/4885KCNJ5 2373/4885KCNJ3 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.